Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2017-02-16

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/acs.jmedchem.6b01694PMID 28139931
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clearance Prediction of Targeted Covalent Inhibitors by In Vitro-In Vivo Extrapolation of Hepatic and Extrahepatic Clearance Mechanisms

  2017cited by this paper
• Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.

  2016cited by this paper
• Development of Selective Covalent Janus Kinase 3 Inhibitors.

  2015cited by this paper
• The Role of Extrahepatic Metabolism in the Pharmacokinetics of the Targeted Covalent Inhibitors Afatinib, Ibrutinib, and Neratinib

  2015cited by this paper
• Selective inhibitors of the Janus kinase Jak3--Are they effective?

  2014cited by this paper
• Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors.

  2014cited by this paper
• Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.

  2014cited by this paper
• An Improved and Efficient Process for the Preparation of Tofacitinib Citrate

  2014cited by this paper
• Tricyclic Covalent Inhibitors Selectively Target Jak3 through an Active Site Thiol*

  2014cited by this paper
• Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.

  2014cited by this paper
• ATP-mediated kinome selectivity: the missing link in understanding the contribution of individual JAK Kinase isoforms to cellular signaling.

  2014cited by this paper
• Developing irreversible inhibitors of the protein kinase cysteinome.

  2013cited by this paper
• Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance

  2013cited by this paper
• Discovery of Novel Spirocyclic Inhibitors of Fatty Acid Amide Hydrolase (FAAH). Part 2. Discovery of 7‐Azaspiro[3.5]nonane Urea PF‐04862853 (I), an orally Efficacious Inhibitor of Fatty Acid Amide Hydrolase (FAAH) for Pain.

  2012cited by this paper
• Selective JAK1 inhibitor and selective Tyk2 inhibitor patents

  2012cited by this paper
• JAK Kinases in Health and Disease: An Update

  2012cited by this paper
• The use of structural biology in Janus kinase targeted drug discovery.

  2011cited by this paper
• Overview of the CCP4 suite and current developments

  2011cited by this paper
• Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.

  2011cited by this paper
• Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 2. Discovery of 7-azaspiro[3.5]nonane urea PF-04862853, an orally efficacious inhibitor of fatty acid amide hydrolase (FAAH) for pain.

  2011cited by this paper
• Features and development of Coot

  2010cited by this paper
• Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6.

  2010cited by this paper
• Recent patents in the discovery of small molecule inhibitors of JAK3

  2010cited by this paper
• Discovery of an Oral Potent Selective Inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS).

  2010cited by this paper
• Photochemical Preparation of a Pyridone Containing Tetracycle: A Jak Protein Kinase Inhibitor.

  2010cited by this paper
• Global kinetic explorer: a new computer program for dynamic simulation and fitting of kinetic data.

  2009cited by this paper
• Fitting enzyme kinetic data with KinTek Global Kinetic Explorer.

  2009cited by this paper
• research papers Acta Crystallographica Section D Biological

  2003cited by this paper
• Optical resolution of 1-benzyl-4-methylpiperidin-3-yl-methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors

  2002cited by this paper
• Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor.

  2002cited by this paper
• Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.

  2000cited by this paper
• Impact of mechanism-based enzyme inactivation on inhibitor potency: implications for rational drug discovery.

  2000cited by this paper
• Recent advances in the cross-coupling reactions of organoboron derivatives with organic electrophiles, 1995–1998

  1999cited by this paper
• Different protein turnover of interleukin-6-type cytokine signalling components.

  1999cited by this paper
• [20] Processing of X-ray diffraction data collected in oscillation mode.

  1997cited by this paper
• Processing of X-ray diffraction data collected in oscillation mode.

  1997cited by this paper
• Refinement of macromolecular structures by the maximum-likelihood method.

  1997cited by this paper
• Mutation of Jak3 in a Patient with SCID: Essential Role of Jak3 in Lymphoid Development

  1995cited by this paper
• The treatment of rheumatoid arthritis.

  1949cited by this paper

• Nitro-Diphenyl Ethers as Emerging Cysteine-Targeting Covalent Warheads Enable Identification of Novel Target LDLRAP1 for Anticoronaviral Activity.

  2026cites this paper
• Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt.

  2026cites this paper
• Expanding landscape of kinase inhibitor research in 25 years (2001-2025) and advancements of next-generation kinase inhibitors.

  2026cites this paper
• Only time will tell: Modelling the kinetics of covalent inhibitors.

  2026cites this paper
• Protein structural dynamics in covalent drug design: insights from irreversible and reversible covalent inhibitors.

  2026cites this paper
• Advancements in research on the cardiovascular toxicity caused by TEC family kinases inhibitors

  2026cites this paper
• Modular Synthetic Platform for the Elaboration of Fragments in Three Dimensions for Fragment-Based Drug Discovery

  2025cites this paper
• Biotransformation research advances – 2024 year in review

  2025influential citation
• Small molecular inhibitors targeting Janus kinases (JAKs) for the treatment of psoriasis.

  2025cites this paper
• Design and Synthesis of Novel Dual Inhibitors for JAK3 and TEC Kinases in Autoimmune Disorders.

  2025cites this paper
• Small-molecule inhibitors in psoriasis: medicinal chemistry insights

  2025cites this paper
• Pharmacophore Modeling of Janus Kinase Inhibitors: Tools for Drug Discovery and Exposition Prediction

  2025cites this paper
• An Asymmetric Reductive Amination Synthesis of Ritlecitinib Using (S)-α-Methylbenzylamine as Chiral Auxiliary.

  2025cites this paper
• Activity Regulation and Conformation Response of Janus Kinase 3 Mediated by Phosphorylation: Exploration from Correlation Network Analysis and Markov Model

  2025cites this paper
• Size-Dependent Target Engagement of Covalent Probes

  2025cites this paper
• Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial

  2025cites this paper
• Research Progress on Virtual Screening Design Techniques for Small Molecule Inhibitors of JAK3 Kinase

  2025cites this paper
• ABT, Elacridar and Bile‐Duct Cannulated Rats: Tools to Understand Pharmacokinetics

  2025cites this paper
• Preparation of ethynylsulfonamides and study of their reactivity with nucleophilic amino acids.

  2025cites this paper
• JAK3 Inhibitors: Covalent and Noncovalent Interactions of a Cyanamide Group Investigated by Multiscale Free-Energy Simulations

  2025cites this paper
• Diversifying the triquinazine scaffold of a Janus kinase inhibitor

  2025cites this paper
• The limitations of small molecule and genetic screening in phenotypic drug discovery.

  2025cites this paper
• Effective virtual screening strategy toward JAK3 covalent inhibitors: combining multi‑conformational consensus calculation with covalent docking.

  2025cites this paper
• Recent advances in ASCT2 inhibitors: ligand design and therapeutic applications.

  2025cites this paper
• Protein targets & therapeutics in psoriasis: toward personalization.

  2025cites this paper
• Organic NMR crystallography: enabling progress for applications to pharmaceuticals and plant cell walls

  2024cites this paper
• Synthesis and clinical application of new drugs approved by NMPA in 2023.

  2024cites this paper
• Exploring Extended Warheads toward Developing Cysteine-Targeted Covalent Kinase Inhibitors

  2024cites this paper
• The significance of chirality in contemporary drug discovery-a mini review

  2024cites this paper
• Harnessing conformational drivers in drug design.

  2024cites this paper
• An allosteric cyclin E-CDK2 site mapped by paralog hopping with covalent probes

  2024cites this paper
• The mechanism of action and chemical synthesis of FDA newly approved drug molecules

  2024cites this paper
• Recent advances in the design of small molecular drugs with acrylamides covalent warheads.

  2024cites this paper
• Synthetic routes and clinical application of new drugs approved by EMA during 2023.

  2024cites this paper
• The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Ritlecitinib, a Janus Kinase 3 and Tyrosine-Protein Kinase Family Inhibitor, in Humans

  2024cites this paper
• Identification of novel covalent JAK3 inhibitors through consensus scoring virtual screening: integration of common feature pharmacophore and covalent docking

  2024cites this paper
• Covalent drug – An emerging framework for targeted drug development

  2024cites this paper
• Structural optimizations on the 7H-pyrrolo[2,3-d]pyrimidine scaffold to develop highly selective, safe and potent JAK3 inhibitors for the treatment of Rheumatoid arthritis.

  2024cites this paper
• Synthesis of Thiazolidin-4-Ones Derivatives, Evaluation of Conformation in Solution, Theoretical Isomerization Reaction Paths and Discovery of Potential Biological Targets

  2024cites this paper
• Small molecule drug discovery targeting the JAK-STAT pathway.

  2024cites this paper
• Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update.

  2024cites this paper
• Structure-property Relationships Reported for the New Drugs Approved in 2023.

  2024cites this paper
• Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on SNAr Electrophiles.

  2024cites this paper
• Design and synthesis of highly selective Janus kinase 3 covalent inhibitors for the treatment of rheumatoid arthritis

  2024cites this paper
• Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model

  2024cites this paper
• Expanding the ligandable proteome by paralog hopping with covalent probes

  2024cites this paper
• Medicinal chemistry perspective of JAK inhibitors: synthesis, biological profile, selectivity, and structure activity relationship

  2024cites this paper
• Synthesis and clinical application of new drugs approved by FDA in 2023.

  2024cites this paper
• JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases

  2023cites this paper
• Design and Molecular Dynamics Simulation of Thieno-pyrimidine derivative JAK3 Inhibitor

  2023cites this paper
• Identification of HHT-9041P1: A novel potent and selective JAK1 inhibitor in a rat model of rheumatoid arthritis.

  2023cites this paper
• Dependence of peripheral T‐cell lymphoma on constitutively activated JAK3: Implication for JAK3 inhibition as a therapeutic approach

  2023cites this paper
• In silico computational drug discovery: a Monte Carlo approach for developing a novel JAK3 inhibitors

  2023cites this paper
• A hybrid energy-based and AI-based screening approach for the discovery of novel inhibitors of JAK3

  2023cites this paper
• Synthesis and clinical application of small-molecule inhibitors of Janus kinase.

  2023cites this paper
• Target Occupancy and Functional Inhibition of JAK3 and TEC Family Kinases by Ritlecitinib in Healthy Adults: An Open‐Label, Phase 1 Study

  2023cites this paper
• A simple method for developing lysine targeted covalent protein reagents

  2023cites this paper
• The Application of pyrrolo[2, 3-d]pyrimidine scaffold in medicinal chemistry from 2017 to 2021.

  2023cites this paper
• Pyrrolo[2,3-d]pyrimidines as EGFR and VEGFR kinase inhibitors: a comprehensive SAR review.

  2023cites this paper
• Current application status and structure-activity relationship of selective and non-selective JAK inhibitors in diseases.

  2023cites this paper
• Expanding the Chemistry of Dihaloacetamides as Tunable Electrophiles for Reversible Covalent Targeting of Cysteines.

  2023cites this paper
• Discovery of novel dual Bruton's tyrosine kinase (BTK) and Janus kinase 3 (JAK3) inhibitors as a promising strategy for rheumatoid arthritis.

  2023cites this paper
• Design, Synthesis and Bioactivity Study of Marine Alkaloid Neobacillamide—A Derivatives

  2023influential citation
• Phosphorylation of Tyrosine 841 Plays a Significant Role in JAK3 Activation

  2023cites this paper
• Docking and Selectivity Studies of Covalently Bound Janus Kinase 3 Inhibitors

  2023cites this paper
• Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance.

  2022cites this paper
• Targeting Janus Kinase (JAK) for Fighting Diseases: The Research of JAK Inhibitor Drugs.

  2022cites this paper
• Design, synthesis and structure-activity relationship studies of pyrido[2,3-d]pyrimidin-7-ones as potent Janus Kinase 3 (JAK3) covalent inhibitors.

  2022cites this paper
• The Ascension of Targeted Covalent Inhibitors.

  2022cites this paper
• Design of Rational JAK3 Inhibitors Based on the Parent Core Structure of 1,7-Dihydro-Dipyrrolo [2,3-b:3′,2′-e] Pyridine

  2022cites this paper
• Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases.

  2022cites this paper
• Novel purine analogues regulate IL-1β release via inhibition of JAK activity in human aortic smooth muscle cells.

  2022cites this paper
• Discovery of Hexahydrofuro[3,2-b]furans as New Kinase-Selective and Orally Bioavailable JAK3 Inhibitors for the Treatment of Leukemia Harboring a JAK3 Activating Mutant.

  2022cites this paper
• A highly selective JAK3 inhibitor is developed for treating rheumatoid arthritis by suppressing γc cytokine–related JAK-STAT signal

  2022cites this paper
• Advances in covalent drug discovery

  2022cites this paper
• (S)-3-(3-((7-Ethynyl-9H-pyrimido[4,5-b]indol-4-yl)amino)piperidin-1-yl)propanenitrile

  2022cites this paper
• Selective inhibitors of JAK1 targeting an isoform-restricted allosteric cysteine

  2022cites this paper
• Covalent Modification of the JH2 Domain of Janus Kinase 2.

  2022cites this paper
• Emerging drugs for the treatment of alopecia areata

  2022cites this paper
• Dioxinodehydroeckol: A Potential Neuroprotective Marine Compound Identified by In Silico Screening for the Treatment and Management of Multiple Brain Disorders

  2022cites this paper
• Discovery and Biological Evaluation of N-Methyl-pyrrolo[2,3-b]pyridine-5-carboxamide Derivatives as JAK1-Selective Inhibitors.

  2021cites this paper
• JAK3 inhibitors for the treatment of inflammatory and autoimmune diseases: a patent review (2016–present)

  2021cites this paper
• IN SILICO MOLECULAR DOCKING STUDY OF CONSTITUENTS FROM APPLE AND PASSION FRUIT FOR THE TREATMENT OF INFLAMMATORY BOWEL DISORDER TARGETING INFLAMMATORY PATHWAY

  2021cites this paper
• Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata

  2021cites this paper
• Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases.

  2021cites this paper
• Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors.

  2021cites this paper
• An alternative process for the synthesis of the key intermediate of ritlecitinib

  2021cites this paper
• Characterization of an aromatic trifluoromethyl ketone as a new warhead for covalently reversible kinase inhibitor design.

  2021cites this paper
• Design, synthesis, and biological evaluation of cyano-substituted 2,4-diarylaminopyrimidines as potent JAK3 inhibitors for the treatment of B-cell lymphoma.

  2021cites this paper
• Recent progress in covalent warheads for in vivo targeting of endogenous proteins.

  2021cites this paper
• Low-dose JAK3-inhibition improves anti-tumor T-cell immunity and immunotherapy efficacy.

  2021cites this paper
• A computational multi-targeting approach for drug repositioning for psoriasis treatment

  2021cites this paper
• JAK Family Inhibitors for Autoimmune Diseases

  2021cites this paper
• INTERPLAY BETWEEN IMMUNITY AND AMYOTROPHIC LATERAL SCLEROSIS: CLINICAL IMPACT.

  2021cites this paper
• Covalent drugs in development for immune-mediated diseases

  2021cites this paper
• Generation of a chemical genetic model for JAK3

  2021cites this paper
• Short enantioselective total synthesis of (+)-tofacitinib

  2021cites this paper
• Functionalized Scout Fragments for Site-Specific Covalent Ligand Discovery and Optimization

  2021cites this paper
• Chemical proteomic identification of functional cysteines with atypical electrophile reactivities.

  2021cites this paper
• Advances in covalent kinase inhibitors.

  2020cites this paper